Brinzolamide and Brimonidine vs Brinzolamide — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Carbonic Anhydrase Inhibitor

Brinzolamide and Brimonidine

Brand: SIMBRINZA

First FDA approval: 2013-05-06

Carbonic Anhydrase Inhibitor

Brinzolamide

Brand: Azopt

First FDA approval: 1998-04-30

Lowest NADACAcquisition cost floor across all NDCs

$26.07Per unit

$10.16Per unit

Average NADACAcross all dosage forms and strengths

$26.07Up to $26.07

$15.72Up to $35.21

Generic manufacturersActive ANDA holders — FDA Orange Book

00 total ANDAs filed

22 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

—Full year

$75.2MFull year

Part D claims (CY24)Total fills, all strengths

—— beneficiaries

332K113K beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

—Per claim, all NDCs

$227Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

2Minimal friction

0Zero PA friction

Step therapy appliedPlan-NDC pairs requiring step therapy

0None

61Limited friction

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Generic availableFDA Orange Book

NoBrand-only

Yes2 manufacturers